A case-control study using motion-inclusive spatial dose-volume metrics to account for genito-urinary toxicity following high-precision radiotherapy for prostate cancer. (July 2018)

• Record Type: Journal Article
• Authors: Casares-Magaz, Oscar; Muren, Ludvig P.; Pettersson, Niclas; Thor, Maria; Hopper, Austin; Knopp, Rick; Deasy, Joseph O.; Væth, Michael; Einck, John; Moiseenko, Vitali
• Is Part Of: Physics and imaging in radiation oncology. Volume 7(2018)
• Page Start: 65
• Page End: 69
• Publication Date: 2018-07
• Subjects: Prostate cancer -- Bladder -- Genitourinary toxicity -- CBCT -- DVH -- Spatial; Radiotherapy -- Periodicals; Radiation dosimetry -- Periodicals; Cancer -- Imaging -- Periodicals; Oncology -- Periodicals; 615.842
• DOI: 10.1016/j.phro.2018.09.005
• Languages: English
• ISSNs: 2405-6316

Abstract

Graphical abstract: Abstract: Background and purpose: The risk of genitourinary (GU) toxicity is dose-limiting in radiotherapy (RT) for prostate cancer. This study investigated whether motion-inclusive spatial dose/volume metrics explain the GU toxicity manifesting after high-precision RT for prostate cancer. Material and methods: A matched case-control was performed within a cohort of 258 prostate cancer patients treated with daily cone-beam CT (CBCT)-guided RT (prescription doses of 77.4–81.0 Gy). Twenty-seven patients (10.5%) presented late RTOG GU ≥ Grade 2 toxicity and those without symptoms of toxicity prior treatment (N = 7) were selected as cases. Each case was matched with three controls based on pre-treatment GU symptoms, age, Gleason score, follow-up time, and hormone therapy. Thirteen CBCTs per patient were rigidly registered to the planning CT using the recorded treatment shifts, and the bladder was manually contoured on each CBCT. Planned and actually delivered dose/volume metrics (the latter averaged across the CBCTs) were extracted from the bladder and its subsectors, and compared between cases and controls (two-way ANOVA test). Results: There were no significant differences between planned and delivered dose/volume metrics; also, there were no significant differences between cases and controls at any dose level, neither for planned nor delivered doses. The cases tended to have larger bladder volumes during treatment than controls (221 ± 71 cm 3 vs 166 ± 73 cm 3 ; p = 0.09). Conclusions: High-precision RT for prostate cancer eliminates differences between planned and delivered dose distributions. Neither planned nor delivered bladder dose/volume metrics were associated to the remaining low risk of developing GU toxicity after high-precision radiotherapy for prostate cancer.